Background: Controlling uterine contractile activity is essential to regulate the duration of pregnancy. During most of the pregnancy, the uterus does not contract (i.e., myometrial quiescence). The myometrium recovers its contractile phenotype at around 36 weeks (i.e., myometrial activation) through several mechanisms. The RHOA/ROCK pathway plays a vital role in facilitating muscular contractions by calcium sensitization in humans. Yet, the role of this pathway during different myometrial stages, including quiescence, has not been elucidated.
Objective: we aimed to study the role of the RHOA/ROCK pathway in the regulation of the different myometrial stages throughout pregnancy. Specifically, we hypothesized that the inhibition of the components of the RHOA/ROCK pathway play an important role in maintaining uterine quiescence.
Study Design: Myometrial samples were obtained from pregnant individuals who underwent cesarean section. Pregnant individuals who delivered preterm without labor (myometrial quiescence), preterm with labor (nonphysiological myometrial stimulation), term not in labor (activation), and term in labor (physiological myometrial stimulation) were included. The mRNA and protein expression of RHOA, ROCK I, ROCK II, RND1-3, and ROCK activity through pMYTP1 were evaluated.
Results: We found that the human myometrium constitutively expressed RHOA/ROCK pathway components throughout pregnancy. No changes in the components of the RHOA/ROCK pathway were found during quiescence. Moreover, the RHOA protein and ROCK activity increased in the myometrium during labor, supporting the hypothesis that this pathway participates in maintaining the contractile activity of the myometrium. This study provides insight into the role of the RHOA/ROCK pathway in controlling myometrial contractile activity during pregnancy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11491706 | PMC |
| http://dx.doi.org/10.1016/j.xagr.2024.100394 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
ATF3 suppresses 3T3-L1 adipocyte adipogenesis via transcriptional repressing USP53.
J Mol Endocrinol
December 2024
M Ye, Department of Pediatrics, Nantong University, Nantong, 226019, China.
Obesity is a widespread nutritional disorder, leading to a strong predisposition towards adverse health consequences. Activating transcription factor 3 (ATF3), a stress-induced transcription factor, has been documented as a therapeutic target for obesity. The intent of this project was to characterize the detailed role of ATF3 in adipogenesis during the process of obesity and its obscure downstream mechanism.
View Article and Find Full Text PDFLoss of NUMB drives aggressive bladder cancer via a RHOA/ROCK/YAP signaling axis.
Nat Commun
December 2024
European Institute of Oncology IRCCS, Milan, Italy.
Advances in bladder cancer (BCa) treatment have been hampered by the lack of predictive biomarkers and targeted therapies. Here, we demonstrate that loss of the tumor suppressor NUMB promotes aggressive bladder tumorigenesis and worsens disease outcomes. Retrospective cohort studies show that NUMB-loss correlates with poor prognosis in post-cystectomy muscle-invasive BCa patients and increased risk of muscle invasion progression in non-muscle invasive BCa patients.
View Article and Find Full Text PDFHydroxysafflor yellow A, a natural food pigment, ameliorates atherosclerosis in ApoE mice by inhibiting the SphK1/S1P/S1PR3 pathway.
Food Sci Nutr
November 2024
Guangdong Metabolic Diseases Research Center of Integrated Chinese and Western Medicine, Key Laboratory of Glucolipid Metabolic Disorder, Ministry of Education of China, Guangdong Key Laboratory of Metabolic Disease Prevention and Treatment of Traditional Chinese Medicine, Institute of Chinese Medicine Guangdong Pharmaceutical University Guangzhou Guangdong China.
Atherosclerosis (AS) is the pathologic basis of many cardiovascular diseases (CVDs). Hydroxysafflor yellow A (HSYA) is a valuable natural food pigment that has been reported to have significant health-promoting abilities. However, the anti-AS efficacy and mechanisms of HSYA have not yet been characterized.
View Article and Find Full Text PDFBroad and diverse roles of sphingosine-1-phosphate/sphingosine-1-phosphate receptors in the prostate.
iScience
December 2024
Department of Urology, Zhongnan Hospital of Wuhan University, Wuhan 430071, China.
Article Synopsis
- Benign prostatic hyperplasia (BPH) is a common issue in older males, but how it develops is still not fully understood, prompting research into the role of sphingosine-1-phosphate (S1P) and its receptors (S1PRs) in the prostate.
- The study found that S1P and its receptors are highly expressed in the prostate, and S1PR1, S1PR2, and S1PR3 are involved in promoting cell growth, muscle contraction, and reducing inflammation via various cellular pathways.
- Treatment with S1P and specific receptor agonists led to prostate enlargement in rats, while antagonists of S1PR1 and S1PR3 reduced BPH symptoms
O-GlcNAcylation in ovarian tumorigenesis and its therapeutic implications.
Transl Oncol
January 2025
Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou 325027, China. Electronic address:
Ovarian cancer is a prevalent malignancy among women, often associated with a poor prognosis. Post-translational modifications (PTMs), particularly O-GlcNAcylation, have been implicated in the progression of ovarian cancer. Emerging evidence indicates that dysregulation of O-GlcNAcylation contributes to the initiation and malignant progression of ovarian cancer.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!